Crispr Therapeutics AG Partners with Sirius on siRNA Tech

Crispr Therapeutics AG ( (CRSP) ) has issued an update.

On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Spark’s Take on CRSP Stock

According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.

Crispr Therapeutics AG’s stock is currently facing significant financial challenges, primarily in terms of revenue generation and profitability. Despite a strong balance sheet, the negative cash flow and earnings metrics weigh heavily on the stock’s performance. Technical analysis indicates mixed signals with short-term momentum but long-term bearish trends. The valuation is unattractive due to the negative P/E ratio and lack of dividends, further impacting the stock’s appeal.

To see Spark’s full report on CRSP stock, click here.

More about Crispr Therapeutics AG

CRISPR Therapeutics AG operates in the biotechnology industry, focusing on the development and commercialization of gene-based medicines. The company is known for its pioneering work in CRISPR/Cas9 gene-editing technology, which is used to treat a variety of genetic diseases.

Average Trading Volume: 2,056,960

Technical Sentiment Signal: Sell

Current Market Cap: $3.35B

See more data about CRSP stock on TipRanks’ Stock Analysis page.